Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/17/2017 11/20/2017 11/21/2017 11/22/2017 11/23/2017 Date
12.55(c) 12.5(c) 11.75(c) 11.95(c) 12.1 Last
109 461 42 084 75 927 82 802 9 849 Volume
+0.40% -0.40% -6.00% +1.70% +1.26% Change
More quotes
Financials (€)
Sales 2017 14,4 M
EBIT 2017 -12,5 M
Net income 2017 -12,6 M
Finance 2017 57,6 M
Yield 2017 -
Sales 2018 11,2 M
EBIT 2018 -23,9 M
Net income 2018 -26,2 M
Finance 2018 38,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 8,74x
EV / Sales2018 13,0x
Capitalization 184 M
More Financials
Company
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.The focus of its treatments includes patients with Parkinson's disease, Rett Syndrome, Amyotrophic Lateral Sclerosis,... 
More about the company
Surperformance© ratings of Newron Pharmaceuticals SpA
Trading Rating : Investor Rating :
More Ratings
Latest news on NEWRON PHARMACEUTICALS SPA
11/16 NEWRON PHARMACEUTICALS : to Participate in Upcoming Investor Conferences in Nove..
11/14 NEWRON PHARMACEUTICALS : to Participate in Upcoming Investor Conferences in Nove..
11/14 NEWRON PHARMACEUTICALS : to Participate in Upcoming Investor Conferences in Nove..
11/10 NEWRON PHARMACEUTICALS : Announces Advisory Board Recommendations and Rett Congr..
11/07 NEWRON PHARMACEUTICALS : Announces Advisory Board Recommendations and Rett Congr..
11/07 Newron Pharmaceuticals Announces Advisory Board Recommendations and Rett Cong..
11/07 NEWRON PHARMACEUTICALS : Announces Advisory Board Recommendations and Rett Congr..
10/27 NEWRON PHARMACEUTICALS : to Present at European Rett Syndrome Congress and Host ..
10/26 NEWRON PHARMACEUTICALS : to Present at European Rett Syndrome Congress and Host ..
10/25 NEWRON PHARMACEUTICALS : to Present at European Rett Syndrome Congress and Host ..
More news
Sector news : Bio Therapeutic Drugs
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/14 Newron Pharmaceuticals SPA reports 1H results
03/02 Newron Pharmaceuticals SPA reports FY results
2016 FDA accepts for review Newron's resubmitted NDA for Xadago; action date March..
2016 Newron Pharmaceuticals SPA reports 1H results
2015 TOP 2 TRADE ALERT IDEAS SEPTEMBER 30 : Esperion Sell-Off, Clovis Milestone, Wind..
Chart NEWRON PHARMACEUTICALS SPA
Duration : Period :
Newron Pharmaceuticals SpA Technical Analysis Chart | NWRN | IT0004147952 | 4-Traders
Technical analysis trends NEWRON PHARMACEUTICALS SPA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 29,2 €
Spread / Average Target 183%
EPS Revisions
Managers
NameTitle
Stefan Weber Chief Executive Officer, Director & IR Contact
Ulrich Köstlin Non-Executive Chairman
Roberto Galli Vice President-Finance
Ravi Anand Chief Medical Officer
Patrick J. Langlois Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS SPA-41.69%217
GILEAD SCIENCES1.16%94 693
REGENERON PHARMACEUTICALS6.67%41 304
VERTEX PHARMACEUTICALS100.10%36 699
GENMAB4.43%11 899
EXELIXIS, INC.76.93%7 707